Retinal Sensitivity in BRVO After Anti-VEGF Therapy
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal
vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully
investigated. The purpose of this study is to compare the changes in retinal sensitivity
after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in
eyes with BRVO.